Opportunities with phage technology and antibody engineering of fusion proteins

Advanced Drug Delivery Reviews

Volumn 22, Issue 3, 1996, Pages 303-313

  Chester, Kerry A ^a   Hawkins, Robert E ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

ADEPT; antibodies; cancer therapy; enzyme therapy; fusion protein

Indexed keywords

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CANCER THERAPY; FUSION PROTEIN; PHAGE TECHNOLOGY; PROTEIN ENGINEERING; TUMOUR;

ANTIBODIES; ANTIGENS; BIOMEDICAL ENGINEERING; DISEASES; ENZYMES;

DRUG THERAPY;

ANTIBODY; DOXORUBICIN; ENZYME; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY PRODUCTION; BACTERIOPHAGE; CANCER THERAPY; DRUG PENETRATION; DRUG TARGETING; ENZYME THERAPY; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; TISSUE DISTRIBUTION;

EID: 0030589522     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00448-6     Document Type: Review

References (53)

1. [1] Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Badger, C.C., Nelp, W.B., Glenn, S., Butchko, G., Fisher, D., Porter, B. et al. (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329, 1219-1224.
2. [2] Reitmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J. and the German Cancer Aid 17-1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma. Lancet 343, 1177-1183.
3. [3] Huston, J.S., McCartney, J., Tai, M.-S., Mottola-Hartshorn, C., Jin, D., Warren, F., Keck, P. and Oppermann, H. (1993) Medical applications of single chain antibodies. Intern. Rev. Immunol. 10, 195-217.
4. [4] Chiswell, D.J. and McCafferty (1992) Phage antibodies: will new 'coliclonal' antibodies replace monoclonal antibodies? TIBTECH 10, 80-84.
5. [5] McCafferty, J., Griffiths, A.D., Winter, G. and Chiswell, D.J. (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554.
6. [6] Yokata, T., Milenic, D.E., Whitlow, M. and Schlom, J. (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402-3408.
7. [7] Milenic, D.E., Yokota, T., Filpula, D.R., Finkelman, M.A.J., Dodd, S.W., Wood, J.F. et al. (1991) Construction, binding properties, metabolism and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51, 6363-6371.
8. [8] Verhaar, M.J., Chester, K.A., Keep, P.A., Robson, L., Pedley, R.B., Boden, J.A., Hawkins, R.E. and Begent, R.H.J. (1995) A single chain FV derived from a filamentous phage library has distinct tumour targeting advantages over one derived from a hybridoma. Int. J. Cancer 61, 497-501.
9. [9] Khawali, L.A., Miller, O.K. and Epstein, A.L. (1994) Effect of several new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumours. Cancer Suppl. 73, 824-831.
10. [10] Savage, P., So, A., Spooner, R.A. and Epenetos, A.A. (1993) A recombinant single chain antibody interleukin-2 fusion protein. Br. J. Cancer 67, 304-310.
11. [11] Kaufman, E.N. and Jain, R.K. (1992) Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res. 52, 4157-4167.
12. [12] Pack, P. and Plückthun, A. (1992) Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry 31, 1579-1584.
13. [13] Holliger, P., Prospero, T. and Winter, G. (1993) Diabodies: small bivalent and bi-specific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444-6448.
14. [14] Neri, D., Mono, M., Prospero, T. and Winter, G. (1995) High affinity antigen binding by chelating recombinant antibodies (CRAbs). J. Mol. Biol. 246, 367-373.
15. [15] Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H.H., Sheuermann, M. and Seemann, G. (1992) Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer 65, 234-238.
16. [16] Orlandi, R., Güssow, D.H., Jones, P.T. and Winter, G. (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86, 3833-3837.
17. [17] Ward, E.S., Güssow, D., Griffiths, A.D., Jones, P.T. and Winter, G. (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 344, 544-546.
18. [18] Zhou, H., Fisher, R.J. and Papas, T.S. (1994) Optimisation of primer sequences for mouse scFv repertoire display library construction. Nuc. Acids Res. 22, 888-889.
19. [19] Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., MacCafferty, J., Griffiths, A.D. and Winter, G. (1991) By-passing immunization: human antibodies from V-gene libraries displayed on bacteriophage. J. Mol. Biol. 222, 581-597.
20. [20] Clackson, T., Hoogenboom, H.R., Griffiths, A.D. and Winter, G. (1991) Making antibody fragments using phage display libraries. Nature 352, 624-628.
21. [21] Hawkins, R.E., Russell, S.J. and Winter, G. (1992) Selection of phage antibodies by binding affinity: mimicking affinity maturation. J. Mol. Biol. 226, 889-896.
22. [22] Roberts, S., Cheethen, J.C. and Rees, A.R. (1987) Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering. Nature 328, 731-734.
23. [23] Reichmann, L. and Weill, M. (1993) Phage display and selection of a site directed randomised single chain antibody Fv fragment for its affinity improvement. Biochemistry 32, 8848-8855.
24. [24] Marks, J.D., Griffiths, A.D., Malmqvist, M., Clackson, T.P., Bye, J.M. and Winter, G. (1992) By-passing immunisation: improving the affinity of a human antibody by chain shuffling. Bio/Technology 10, 779-783.
25. [25] Wei-Ping, Y., Green, K., Pinz-Sweeny, S., Briones, A.T., Burton, D.R. and Barbas, C.F. III. (1995) CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV antibody into the picomolar range. J. Mol. Biol. 254, 392-403.
26. [26] Chester, K.A., Begent, R.H.J., Robson, L., Keep, P., Pedley, R.B., Boden, J.A., Boxer, G., Green, A., Winter, G., Cochet, O. and Hawkins, R.E. (1994) Phage libraries for generation of clinically useful antibodies. Lancet 343, 455-456.
27. [27] Riechmann, L., Clark, M., Waldmann, H. and Winter, G. (1988) Reshaping human antibodies for therapy. Nature 332, 323-327.
28. [28] Roguska, M.A., Pedersen, J.T., Keddy, C.A., Henry, A.H., Searle, S.J., Lambert, J.M., Goldmacher, V.S., Blattler, W.A., Rees, A.R. and Guild, B.C. (1994) Humanisation of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA 91, 969-973.
29. [29] Lonberg, N., Taylor, L.D., Harding, P.A., Trounstine, M., Higgins, K.M., Schramm, S.R., Kuo, C.-C, Mashayekh, R., Wymore, K., McCabe, J.G., O'Regan, D.M., O'Donnell, S.L., Lapachet, E.S.G., Benoechea, T., Fishweld, D.M., Carmack, C.E., Kay, R.M. and Huszar, D. (1994) Antigenspecific human antibodies from mice comprising four distinct genetic modifications. Nature 368, 856-859.
30. [30] Green, L.L., Hardy, M.C., Maynard-Currie, C.E., Tsuda, H., Louie, D.M., Mendez, M.J., Abderrahim, H., Noguchi, M., Smith, D.H., Zeng, Y., David, N.E., Sasai, H., Garza, D., Brenner, D.G., Hales, J.F., McGuinnes, R.P., Capon, D.J., Klapholz, S. and Jokobovits, A. (1994) Antigen specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7, 13-21.
31. [31] Griffiths, A.D., Williams, S.C., Hartley, O., Tomlinson, I.M., Waterhouse, P., Crosby, W.L., Kontermann, R.E., Jones, P.T., Low, N.M., Allison, T.J., Prospero, T.D., Hoogenboom, H.R., Nissim, A., Cox, J.P.L., Harrison, J.L., Zacculo, M., Gherardi, E. and Winter, G. (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245-3260.
32. [32] Vaughan, T.J., Williams, A.J., Prithard, K., Osbourne, J.K., Pope, A.R., Earnshaw, J.C., McCafferty, J., Hodits, R.A., Wilton, J. and Johnson, K.S. (1996) Human antibodies with sub-nanomalar affinities isolated from a large non-immunised phage display library. Nature Biotechnology 14, 309-314.
33. [33] Winter, G., Griffiths, A.D., Hawkins, R.E. and Hoogenboom, H.R. (1994) Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455.
34. [34] Pollack, S.J., Jacobs, J.W. and Schultz, R.G. (1986) Selective chemical catalysis by an antibody. Science 234, 1570-1573.
35. [35] Tramontano, A., Janda, K.D. and Lerner, R.A. (1986) Chemical reactivity at an antibody binding site elicited by mevhanistic design of a synthetic antigen. Proc. Natl. Acad. Sci. USA 83, 6736-6740.
36. [36] Tramontano, A., Janda, K.D. and Lerner, R.A. (1986) Catalytic antibodies. Science 234, 1566-1570.
37. [37] Wentworth, P., Datta, A., Blakey, D., Boyle, D., Partridge, L.J. and Blackburn, M. (1996) Toward antibody-directed 'abzytne' prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumour cell killing. Proc. Natl. Acad. Sci. USA 93, 799-803.
38. [38] Schlom, J., Eggensperger, D., Colcher, D., Molinolo, A., Houchens, D., Miller, L.S., Hinkle, G. and Siler, K. (1992) Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res. 52, 14-1072.
39. [39] Adams, G.P., Shier, R., Mcartney, J.E., McCall, A.M., Wolf, E.J., Tai, M.-S., Stafford, W.F., Houston, L.L., Huston, J.S., Marks, J.D. and Weiner, L.M. (1996) Influence of affinity, avidity and size on the tumour retention of anti-c-erbB-2 single chain Fv molecules. Poster 300, Keystone Symposia: exploring and exploiting antibody and Ig superfamily combining sites (D1) Taos, New Mexico Feb. 22-28. Immunotechnology (in press).
40. [40] Vriesendorp, H.M., Herpst, J.M., Germack, M.A., Klein, J.L., Leichner, P.K., Loudenslager, D.M. et al. (1991) Phase I-II studies of yttrium-labelled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J. Clin. Oncol. 9, 918-928.
41. [41] Pai, L.H., Bookman, M.A., Ozols, R.F., Young, R.C., Smith, J.W., Longo, D.L., Gould, B., Frankel, A., McClay, E.F., Howell, S., Reed, E., Willingham, M.C., Fitzgerald, D.J. and Pastan, I. (1991) Clinical evaluation of intraperitoneal pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J. Clin. Oncol. 9, 2095-2103.
42. [42] Kennel, S.J. (1991) Effects of target antigen competition on distribution of monoclonal antibody to solid tumors. Cancer Res. 52, 1284-1290.
43. [43] De Kruif, J., Terstappen, L., Boel, E. and Logtenberg, T. (1996) Rapid selection of a cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sci. USA 92, 3938-3942.
44. [44] Chi, X. and Garen, A. (1996) Anti-melanoma antibodies from melanoma patients immunised with genetically modified autologous tumour cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc. Natl. Acad. Sci. USA 92, 6537-6541.
45. [45] Urban, J.L. and Schreiber, H. (1992) Tumor antigens. Ann. Rev. Immunol. 10, 617-644.
46. [46] Bagshawe, K.D., Sharma, S.K., Springer, C.J. and Antoniw, P. (1995) Antibody directed prodrug therapy: pilot scale clinical trial. Tumour Targeting 1, 1-13.
47. [47] Sharma, S.K., Bagshawe, K.D., Springer, C.J., Antoniw, P., Boden, J.A., Rogers, G.T., Burke, P.J., Melton, R.G. and Sherwood, R.F. (1991) Antibody directed enzyme prodrug therapy (ADEPT) - a three phase system. Dis. Markers 9, 225-231.
48. [48] Bosslet, K., Czech, J. and Hoffmann, D. (1994) Tumour-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 54, 2151-2159.
49. HER2 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55, 63-70.
50. [50] Burrows, F.J. and Thorpe, P.E. (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA 90, 8996-9000.
51. [51] Gosborn, S.C., Svensson, H.P., Kerr, D.E., Somerville, J.E., Senter, P.D. and Fell, H.P. (1993) Genetic construction, expression and characterisation of a single chain anti-carcinoma antibody fused to beta-lactamase. Cancer Res. 53, 2123-2127.
52. [52] De Sutler, K. and Fiers, W, (1994) A bifunctional murine:human chimeric antibody with one antigen-binding arm replaced by bacterial β-lactamase, Mol. Immunol. 31, 261-267.
53. [53] Michael, N.P., Chester, K.A., Melton, R.G., Robson, L., Nicholas, W., Boden, J.A., Pedley, R.B., Begent, R.H.J., Sherwood, R.F. and Minton, N.P. (1996) In vitro and in vivo characterisation of a recombinant carboxypeptidase G2:anti-CEA scFv fusion protein. Immunotechnology 2, 47-57.